To the MS Community:
Biogen Idec and Elan launched TYSABRI® (natalizumab) in some countries in Europe and reintroduced the product in the U.S. This represents an important step forward for people living with multiple sclerosis (MS), and we believe TYSABRI offers new hope in the management of this debilitating disease.
We are implementing risk management plans in the U.S. and Europe to facilitate appropriate use of TYSABRI, to inform benefit-risk discussions between physicians and patients and to assess the incidence and rate of progressive multifocal leukoencephalopathy (PML) and serious opportunistic infections. As Biogen Idec, Elan and the FDA have stated previously, we anticipate there will be additional cases of PML with the use of TYSABRI. In addition, we expect that for the foreseeable future there will be many rumors and speculation regarding TYSABRI and suspected cases of PML. We expect to communicate critical information about TYSABRI to the MS community and other stakeholders at the appropriate time and manner.
2006 TYSABRI® News Archive